pain modulation News
-
Nerivio® Drug-free Wearable Surpasses 100,000 Migraine Treatments in the US
Theranica, a prescribed digital therapeutics company developing advanced electroceuticals for migraine and other pain conditions, today announced it has seen consistent growth in the usage of Nerivio, marking more than 100,000 treatments in the USA. "We are at a crossroads for acute migraine treatment, where traditional drug-based solutions are being challenged by FDA-authorized, novel digital ...
-
Theranica Announces the Establishment of a Unique Level II HCPCS Code by the Centers for Medicare and Medicaid Services (CMS)
Theranica, a prescribed digital therapeutics company developing advanced electroceuticals for migraine and other pain conditions, today announced that the Centers for Medicare and Medicaid Services (CMS) published its most recent Level II Healthcare Common Procedure Coding System (HCPCS), assigning a new HCPCS Level II code K1023 "Distal Transcutaneous Electrical Nerve Stimulator, Stimulates ...
-
Peer-Reviewed Published Study Provides Further Evidence for the Safety and Efficacy of Nerivio in Patients with Chronic Migraine
Theranica, a prescribed digital therapeutics company developing advanced electroceuticals for migraine and other pain conditions, announced today a new peer-reviewed article, with the publication of a chronic migraine study by Pain Reports. The prospective, multi-center, open-label trial (NCT04194008), evaluated the efficacy and safety of remote electrical neuromodulation (REN) for the acute ...
-
Healthcare Industry Leader Scott Serota Joins Theranica Board of Directors
Theranica, a prescribed digital therapeutics company developing advanced electroceuticals for migraine and other pain conditions, today announced the appointment of Scott Serota to its Board of Directors. "Over the course of the past few decades, which I have dedicated to enabling patients of various medical conditions access to new treatments, I developed passion for supporting the advancement ...
-
FDA Approves Theranica`s Nerivio® for Acute Treatment of Migraine in Adolescents
Theranica, a prescribed digital therapeutics (PDT) company developing advanced electroceuticals for migraine and other pain conditions, today announced that its Nerivio® therapeutic device has received the Food and Drug Administration clearance to market for an expanded indication for acute treatment of episodic or chronic migraine in people 12 years and older. The use of the device in the ...
-
Panag Pharma announces health Canada License for a topical cold-sore formulation NPN 80084806
Halifax, Nova Scotia. Panag Pharma announces Health Canada approval for a topical Cold-Sore Formulation, a new generation topical formulation with a dual mechanism of action that improves healing rates and reduces symptoms, i.e. pain, associated with herpes labialis (cold sores). The topical Cold-Sore Formulation is a natural health product indicated for the relief of symptoms associated ...
-
Panag Pharma Announces Health Canada License for Topical A OTC (NPN 80070485)
Panag Pharma announces Health Canada approval for Topical AOTC, a new generation topical formulation with a dual mechanism of action against pain. Topical AOTC is a natural health product indicated for temporarily relief of aches and pains of muscles and joints associated with simple backache, lumbago, strains and sprains and arthritis. Topical AOTC uses a novel technology targeting the ...
-
Panag Pharma Announces Patent Grant
Panag Pharma Inc., announces that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Application Serial Number 14/722,991 Entitled: COMPOSITIONS AND METHODS FOR TREATMENT OF OCULAR INFLAMMATION AND/OR PAIN, a patent which protects its novel topical ocular product formulations. Panag Pharma’s ocular formulation leverages a novel drug platform ...
-
Nalu and Nevro Reach Settlement in Patent Infringement Lawsuit
Nalu Medical, Inc. announced today that Nalu and Nevro Corporation have reached a settlement in the patent infringement lawsuit brought by Nevro in February 2020. “We are very pleased that we are able to put this litigation behind us, while maintaining our current menu of therapy options,” said Earl Fender, CEO. Nalu is a California-based company with miniaturized, ...
-
Nalu Medical Announces Scientific Presentations at 2021 North American Neuromodulation Society (NANS) Mid-Year Meeting
Nalu Medical, Inc. (“Nalu”), a California-based company that has successfully miniaturized neurostimulation implants for chronic intractable pain management indications, announced that the scientific presentation schedule during the 2021 North American Neuromodulation Society (NANS) Mid-Year Meeting in Orlando, Florida will include three abstract submissions all selected for oral ...
-
R&D 100 Award for IT/Electrical Technology is Fourth Prestigious Win for Nalu Medical
Nalu Medical, Inc. (“Nalu”) is named the R&D 100 Award winner for IT/Electrical technology. For nearly 60 years, the coveted R&D 100 Awards have recognized new products for their technological significance in industry sectors spanning telecommunications, high-energy physics, software, manufacturing, and biotechnology. This is the fourth major award1,2,3 recognizing Nalu for ...
-
Nalu Medical, Inc. Names Thomas West President and Chief Executive Officer
Nalu Medical, Inc. (“Nalu”), a private company focused on innovative and minimally invasive solutions for chronic neuropathic pain, announced today that the Board of Directors has appointed Thomas “Tom” West as President and Chief Executive Officer. This leadership appointment is effective on August 8th and follows the decision by Earl Fender, Nalu’s current CEO, to ...
-
Nalu Medical Named Best MedTech Company and Medical Device in Field of Neurology
Nalu Medical is pleased to announce its flagship micro-Implantable Pulse Generator (mIPG™) was selected as the 2021 winner of the MedTech Visionaries Award for Best MedTech Company and Best Medical Device in the field of neurology. The MedTech Visionaries Awards honor organizations that apply science and technology to real-world problems to advance MedTech solutions for businesses and ...
-
Nalu Medical Releases “Haleakala” Update, Extending Pulse Width Range and Unlocking the System’s Patient Activity Monitor
Nalu Medical (“NALU”) announces the “Haleakala” update, substantially upgrading both the software and firmware of their award-winning Nalu Neurostimulation System. This update adds significant new capabilities for both spinal cord stimulation (SCS) and peripheral nerve stimulation (PNS). The update broadens the stimulation pulse width parameter to the widest range ...
-
Nalu Medical kicks-off ‘Engineered to be More’ with new product releases and software upgrade to provide more therapy options and support for its patients and physicians
Nalu Medical, Inc. (“Nalu”), a Carlsbad, California-based company that has successfully miniaturized neurostimulation implants for the management of intractable chronic pain for both Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS) indications, launches its ‘Engineered to be More’ branding campaign. The campaign highlights the award-winning engineering ...
-
Neurolief Announces Exclusive Licensing Agreement with NeuroFront for Development and Commercialization of Relivion in Greater China and South Korea
Neurolief, an Israel-based company pioneering neuromodulation for the treatment of chronic neurological and neuropsychiatric disorders, and NeuroFront, a clinical stage biotech company focusing on innovative neuroscience therapies, jointly announced an exclusive licensing agreement for NeuroFront to develop and commercialize Relivion, non-invasive medical devices for the treatment of migraine and ...
-
Relivion Wearable Brain Neuromodulation Technology Cleared by FDA for the Treatment of Migraine
Neurolief, an innovator in neurotechnology, announces the company has received Food and Drug Administration (FDA) clearance for its Relivion® system. Relivion® is the first non-invasive multi-channel brain neuromodulation system for at home treatment of acute migraine, a debilitating neurological disease impacting 39 million people and resulting in 1.2 million emergency department visits ...
-
Neurolief and Sawai Enter into Exclusive Development and Marketing Agreement for Relivion
Neurolief Ltd., a neurotechnology innovator, today announces that it has entered into an exclusive agreement with Sawai Pharmaceutical Co., Ltd. for the development and marketing of Relivion®, a non-invasive digital medical device for migraine and depression, in Japan. Relivion® is a non-invasive brain neuromodulation* device that is placed around the head and delivers unparalleled ...
-
Neurolief Announces Positive Results From RIME Clinical Study of Its Brain Neuromodulation System for Treating Acute Migraine
Neurolief, a neurotechnology innovator, today announces findings of the RIME US pivotal trial that demonstrate the safety and efficacy of the Relivion®, a novel external brain neuromodulation system for self-administered treatment of migraine. The study met all its endpoints with statistical significance. “The results of this study are extremely promising for those seeking an ...
-
Neurolief Awarded Breakthrough Device Designation from FDA for Wearable Technology to Address Major Depression
Neurolief, a medical neurotechnology innovator, today announces that the US Food and Drug Administration (FDA) has granted Breakthrough Device designation to the Relivion®DP system, the first non-invasive multi-channel brain neuromodulation technology, for the treatment of major depression. A wearable device, the Relivion®DP system is designed as an adjunctive treatment to pharmaceutical ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you